(ICCM) IceCure Medical Ltd Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ICCM) IceCure Medical Ltd Complete Analysis Pack
IceCure Medical’s Business Model, Simplified
Unlock the full strategic blueprint behind IceCure Medical Ltd’s business model. This concise Business Model Canvas maps how the company creates value, reaches customers, and supports growth in a competitive medtech market. If you want a clearer view of its strategy, risks, and revenue logic, the full canvas is the next step.
Partnerships
Oncology hospitals
Oncology hospitals and specialty cancer centers are the core clinical partners for IceCure Medical Ltd’s ProSense, giving it access to procedure volume and breast cancer physicians. Breast cancer remains the world’s most diagnosed cancer, with about 2.3 million new cases a year, so these sites are key to real-world outcome data and faster adoption.
Clinical investigators
Clinical investigators, especially breast surgeons, help IceCure Medical Ltd build the safety and efficacy data needed for its focused cryoablation indication. Their published studies also help define patient selection and strengthen market credibility as the Company pushes for broader adoption and reimbursement.
International distributors
International distributors help IceCure Medical Ltd sell beyond Israel and the US, cutting the need to build full sales teams in every country. They also handle local registration, import logistics, and hospital access, which can speed market entry and lower fixed costs versus direct country expansion.
Component suppliers
IceCure Medical Ltd depends on component suppliers for device parts, cryogenic inputs, and packaging, and medical devices need full lot traceability under controlled manufacturing. Reliable sourcing lowers shortage risk and helps protect quality, while weak supplier performance can lift costs and trigger regulatory issues.
- Secure critical device and cryogenic parts
- Track lots for full traceability
- Protect supply continuity and quality
- Manage cost and compliance risk
Regulatory and reimbursement advisors
Regulatory and reimbursement advisors help IceCure Medical Ltd prepare FDA and payer submissions, which is critical because cryoablation only scales when it has clear market authorization and coverage. Their work cuts execution risk in a market where approval can unlock adoption but reimbursement still decides if hospitals will pay.
- Support FDA and payer filings
- Build market access arguments
- Reduce regulatory execution risk
- Speed hospital adoption decisions
IceCure’s Key Partners Power ProSense Adoption and Market Access
IceCure Medical Ltd’s key partners are oncology hospitals, breast surgeons, distributors, suppliers, and regulatory or reimbursement advisers. These ties matter because breast cancer still drives about 2.3 million new cases a year, so each partner helps prove ProSense outcomes, expand access, and support FDA and payer clearance.
| Partner | Role | Value |
|---|---|---|
| Hospitals | Cases | Adoption |
| Surgeons | Data | Evidence |
| Distributors | Local sales | Reach |
What is included in the product
Detailed Word Document
A concise, real-world BMC of IceCure Medical Ltd covering its cryoablation oncology strategy, partners, channels, customers, and revenue model.
Customizable Excel Spreadsheet
Quickly maps IceCure Medical Ltd’s pain-point-reliever model in a clear, one-page business snapshot.
Reference Sources
Provides a credible reference trail for IceCure Medical Ltd, helping users verify assumptions fast and make better decisions.
Activities
Cryoablation R and D
IceCure Medical Ltd’s core R&D activity is refining freezing-based tumor ablation around the ProSense system, with work focused on probe design, device performance, and tighter treatment control. The company keeps engineering active to widen clinical indications and make the platform easier to use in real-world procedures, where precision and workflow speed matter most.
Clinical evidence generation
Clinical evidence generation is central to IceCure Medical Ltd, because trials must prove safety and effectiveness to physicians, regulators, and payers. Breast tumor data is the key commercial proof point, since it drives adoption of ProSense and supports label expansion; in 2025, IceCure reported $0.7 million in revenue and $27.4 million in cash and short-term deposits, so study data also helps attract funding for growth.
Regulatory submissions
Regulatory submissions are a core operating task for IceCure Medical Ltd, because every new market needs filings, testing, and quality-system proof under rules like FDA 21 CFR Part 820 and EU MDR 2017/745. These workstreams support U.S. and global market access, and they are a constant cost for a device company, not a one-time step.
Manufacturing and quality control
IceCure Medical Ltd must manufacture each cryotherapy device under tight quality controls, because sterility and repeatability are critical in a clinical procedure room. Manufacturing efficiency also shapes gross margin and buyer trust; in its latest filings, the Company remained pre-profit, so every unit’s yield and reliability directly affect cash burn and confidence.
- Strict sterility and safety checks
- Stable output supports gross margin
- Reliability matters in procedures
Sales training and support
Sales training and support are central to IceCure Medical Ltd’s commercial model because physicians and hospital teams must learn patient selection and the ProSense workflow before adoption. With ProSense already used in 30+ countries, hands-on support helps cut setup friction, speed repeat use, and protect retention in a niche device market.
- Trains clinicians on patient fit
- Explains procedure workflow step by step
- Reduces adoption barriers
- Supports repeat use and retention
IceCure’s 2025: Cash-Rich, Proof-Driven Growth Story
IceCure Medical Ltd’s key activities are R&D, clinical trials, regulatory filings, and ProSense manufacturing and support. In 2025, IceCure Medical Ltd reported $0.7 million revenue and $27.4 million cash and short-term deposits, so proof generation and execution still drive the model.
| Metric | 2025 |
|---|---|
| Revenue | $0.7 million |
| Cash and short-term deposits | $27.4 million |
| Countries with ProSense use | 30+ |
Full Document Unlocks After Purchase
Business Model Canvas
This IceCure Medical Ltd Business Model Canvas preview is the real document you’ll receive after purchase, not a sample or mockup. It reflects the same structure, content, and formatting shown here, so you know exactly what to expect. Once you buy, you’ll get full access to this same ready-to-use file.
Resources
ProSense system
ProSense is IceCure Medical Ltd’s core cryoablation platform, used to freeze and destroy human tumors, especially breast tumors. It is the company’s main commercial asset, and the installed base and clinical adoption of this system drive sales, with IceCure reporting $5.6 million in 2024 revenue.
Cryoablation intellectual property
IceCure Medical Ltd relies on cryoablation patents and proprietary know-how to protect its technology base, reduce direct imitation risk, and strengthen licensing talks. In medical devices, IP is a core moat: the company’s latest filings show an active patent portfolio across key markets, which matters when competitors sell similar minimally invasive systems.
Clinical data set
IceCure Medical Ltd’s clinical data set is a key asset because it builds physician trust, supports FDA and other regulatory filings, and strengthens reimbursement talks. Breast tumor evidence matters most: breast cancer is about 1 in 8 U.S. women over a lifetime, so strong outcomes data helps ProSense stand out from other ablation options.
Regulatory approvals and filings
Regulatory approvals and filings are core key resources for IceCure Medical Ltd because they define where ProSense can be sold and used; every new market needs a cleared dossier, safety data, and compliance record. In medtech, these assets cut commercialization friction, and IceCure’s FDA clearance and CE-marked access have been central to its market entry path.
- Enable market access
- Support FDA and CE filings
- Store compliance evidence
- Reduce launch barriers
Caesarea, Israel team
IceCure Medical Ltd's Caesarea, Israel team is a core key resource: its engineering, clinical, and commercial staff drive product development, regulatory work, and global execution from headquarters in Caesarea, Israel. In a specialized device business, this human capital matters as much as the IP, because a focused team keeps the cryoablation platform moving from R&D to market.
- Headquarters and core staff are in Caesarea, Israel.
- Engineering, clinical, and commercial roles run execution.
- Specialized human capital supports global operations.
IceCure’s Core Assets Power Its $5.6M Revenue Base
IceCure Medical Ltd’s key resources are ProSense, its cryoablation IP, clinical evidence, regulatory clearances, and a Caesarea-based team. These assets supported $5.6 million of 2024 revenue and remain the base for market access and adoption.
| Resource | Data |
|---|---|
| ProSense | Core revenue asset |
| 2024 revenue | $5.6 million |
| HQ | Caesarea, Israel |
Value Propositions
Minimally invasive treatment
IceCure Medical Ltd’s cryoablation uses targeted freezing through a probe, not open excision, so it is a less invasive option for selected patients. This can reduce procedural burden and support faster recovery versus surgery; in breast cancer care, minimally invasive treatment is also a strong clinical and commercial advantage for the 2 million new cases diagnosed worldwide each year.
Breast tumor focus
IceCure Medical Ltd’s breast tumor focus gives ProSense a clear, single-use case in breast lesion cryoablation, which sharpens clinical evidence, messaging, and sales effort. That focus matters in a big market: breast cancer caused about 2.3 million new cases worldwide in 2022, so even a narrow indication can help adoption in specialty breast centers.
Freezing-based tumor destruction
IceCure Medical’s core value is cryoablation: freezing destroys tumor tissue, rather than using heat or surgery. In selected cases, that can spare more healthy tissue and help the company stand out in minimally invasive cancer care. The technology remains central to IceCure Medical’s business model and product positioning.
Office or outpatient workflow
IceCure Medical Ltd’s office or outpatient workflow fits lower-resource settings because ProSense procedures are designed to avoid major surgery, general anesthesia, and long recovery. In a 2025 outpatient market where clinics still face capacity strain, a faster, simpler workflow is a clear selling point for patient convenience and room turnover.
- Less resource-heavy than surgery
- Supports local-anesthesia use
- Improves clinic throughput
- Raises patient convenience
Alternative for selected patients
IceCure Medical Ltd’s ProSense offers a non-surgical option for selected patients, adding a practical path for people who may not want or qualify for surgery. In the ICE3 study, 225 women with low-risk invasive breast cancer were treated, showing why having more than one tool can make physician adoption easier and broaden use cases.
- Non-surgical choice for selected patients
- Fits patients who want less invasive care
- Gives physicians more treatment options
- Expands platform value across cases
Non-Surgical Tumor Freezing, Faster Recovery
IceCure Medical Ltd’s main value is non-surgical cryoablation: ProSense freezes selected tumors through a probe, helping spare healthy tissue and support faster recovery than open surgery. The workflow is built for outpatient use, so it can cut anesthesia, room time, and recovery burden.
| Value proposition | Data point |
|---|---|
| Selected breast cancer use | ICE3 studied 225 women |
| Market need | About 2.3 million new breast cases in 2022 |
| Care setting | Outpatient, local-anesthesia fit |
Customer Relationships
Direct hospital selling
IceCure Medical Ltd likely manages direct ties with hospital buyers and clinicians, which fits medtech’s account-based sales model; buying groups often include 6-10 stakeholders, so face-to-face selling helps with product education and contract talks.
That channel also keeps feedback loops tight, so field teams can pass hospital input back fast and adjust rollout, training, and usage support as adoption grows.
Clinical onboarding
Clinical onboarding is key for IceCure Medical Ltd because physicians need training before using a new ablation platform: case selection, device use, and workflow fit. Clear onboarding reduces misuse, builds confidence, and supports repeat utilization, which matters because adoption is strongest when the first cases run smoothly.
Procedure support
Procedure support is central for IceCure Medical Ltd because ProSense depends on physician technique, so clinical guidance in early cases can speed adoption and reduce room-time friction. Ongoing field support during procedures builds confidence, helps preserve consistent execution, and supports loyalty as doctors move from first use to repeat use.
Key opinion leader engagement
Key opinion leader engagement helps IceCure Medical Ltd turn specialist physicians into clinical validators and advocates, which is vital in device markets with procedure-heavy adoption. KOL input supports education, raises visibility, and builds trust, helping spread acceptance after public clinical readouts such as the 2025 ICE3 follow-up data.
- Validates cryoablation use
- Drives peer-to-peer adoption
- Supports education and trust
Long-term account management
Long-term account management keeps IceCure Medical Ltd in hospital accounts after the first sale, with service, training, and product replenishment driving repeat use. In recurring medtech sales, this is what turns a single placement into a longer revenue stream and helps expand usage across more procedures and sites.
- Service keeps systems active
- Training supports clinical adoption
- Replenishment supports repeat sales
IceCure Wins Through Hospital Relationships and Hands-On Training
IceCure Medical Ltd’s customer relationships are account-based: it sells to hospital buying groups and clinicians, then supports onboarding, procedure use, and repeat adoption. In medtech, 6-10 stakeholders often shape one purchase, so face-to-face education matters.
KOLs and field teams help validate cryoablation, train doctors, and keep feedback flowing after first cases.
| Focus | Data |
|---|---|
| Buying group size | 6-10 stakeholders |
| Primary link | Hospitals and clinicians |
| Support need | Training and field help |
Channels
Direct sales force
Direct sales force is a strong fit for IceCure Medical Ltd because specialty medical devices need close hospital and physician access, education, and contract support. The team can focus on a niche platform like ProSense across 3 key indications, which helps reach high-value accounts and manage a long, technical sales cycle.
Distributor network
IceCure Medical Ltd uses distributor networks to reach foreign markets without building full local sales teams, letting partners handle language, logistics, and hospital selling. For a smaller medtech company with limited scale, this channel can cut market-entry cost and speed international coverage.
Medical conferences
Medical conferences are a key promotion channel for IceCure Medical Ltd because they let the Company show cryoablation systems to surgeons, oncologists, and hospital buyers in person. Major oncology congresses like ASCO draw 40,000+ attendees and thousands of abstracts, so conference visibility helps build awareness, trust, and scientific credibility fast.
Clinical publications
Clinical publications are a high-trust channel for IceCure Medical Ltd because physicians often want peer-reviewed evidence before adopting a new cryoablation system. Published studies also help in payer and regulator talks by showing clinical outcomes, safety, and use cases in real care settings.
- Builds evidence-based demand
- Supports physician adoption
- Helps reimbursement talks
- Strengthens regulatory credibility
Digital product materials
Digital product materials are a key lead tool for IceCure Medical Ltd: web content, brochures, and technical sheets help physicians and distributors understand the ProSense cryoablation procedure and device features fast. In medtech, clear educational content cuts back-and-forth, so it can shorten the sales cycle and support adoption.
- Explains procedure and device use
- Supports physicians and distributors
- Helps convert leads faster
How IceCure Builds Trust and Adoption for ProSense
IceCure Medical Ltd’s channels mix direct sales, distributors, conferences, publications, and digital materials to reach hospitals and physicians for ProSense. This fits a long, evidence-led medtech cycle, where ASCO draws 40,000+ attendees and peer-reviewed data helps adoption.
| Channel | Why it matters | Data |
|---|---|---|
| Conferences | Builds trust | ASCO 40,000+ |
| Publications | Supports adoption | Peer-reviewed evidence |
Customer Segments
Breast surgeons
Breast surgeons are IceCure Medical Ltd’s main physician users, and they decide whether cryoablation moves into routine care. With breast cancer causing about 2.3 million new cases worldwide each year, their focus is on efficacy, fast workflow, and clear patient selection, which makes them the key driver of product uptake.
Oncology hospitals
Oncology hospitals are IceCure Medical Ltd's main buyers, because they assess clinical fit, device economics, and expected procedure volumes before approval. Hospital accounts sit at the center of revenue, and adoption usually depends on departmental budgets, reimbursement, and whether the device can support enough cases to justify the spend.
Cancer treatment centers
Specialty cancer treatment centers are a strong fit for IceCure Medical Ltd because they already have experienced clinicians, imaging suites, and the procedural volume needed to adopt ProSense quickly. With global cancer cases at 20 million in 2022 and projected to reach 35 million by 2050, these centers can act as reference sites that help drive broader market acceptance.
Interventional specialists
Interventional radiologists and other procedure-based specialists are a key user group for IceCure Medical Ltd, because cryoablation fits minimally invasive tumor care in selected settings. Their adoption depends on hands-on training and clinical evidence, which can broaden the addressable market as procedure volumes shift toward image-guided treatments.
- Procedure-based specialists support selected use
- Training drives adoption and confidence
- Evidence matters for broader market reach
- Minimally invasive care is the main pull
International distributors
International distributors are channel customers for IceCure Medical Ltd: they buy access rights or inventory, then resell in local markets. Their value depends on clinical demand and regulatory approvals, so this segment directly supports geographic expansion and faster market entry.
IceCure reported revenue of $0.7 million in 2023, showing how distributor reach matters for scaling adoption.
- Buy for resale
- Need regulatory clearance
- Depend on local demand
IceCure’s Growth Hinges on Hospitals, Evidence, and Market Access
IceCure Medical Ltd serves breast surgeons, oncology hospitals, specialty cancer centers, interventional radiologists, and international distributors. Demand is driven by selected cryoablation use, where adoption depends on clinical evidence, training, reimbursement, and procedure volume.
The biggest buying power sits with hospitals and cancer centers, while distributors help IceCure Medical Ltd expand into local markets. In 2023, IceCure Medical Ltd reported $0.7 million revenue, showing how early-stage the segment mix still is.
| Segment | Role |
|---|---|
| Breast surgeons | Primary physician users |
| Oncology hospitals | Main buyers |
| Specialty cancer centers | Reference sites |
| Distributors | Local market access |
Cost Structure
Research and development
Research and development is a core cost for IceCure Medical Ltd, covering engineering, prototyping, testing, and iteration. For a medtech growth company, this spend is not optional: it supports product upgrades and helps keep the Company competitive as it scales.
Clinical trial expenses
Clinical trial expenses are a major cost driver for IceCure Medical Ltd because studies need trial sites, investigators, monitoring, and data management, and costs climb fast with longer, more complex studies. As IceCure advances evidence generation for regulatory and commercial goals, these trials remain one of its largest investment areas.
Manufacturing and supply chain
Manufacturing and supply chain are a core cost driver for IceCure Medical Ltd because its cryoablation devices need controlled assembly, validated components, and strict quality systems. Any supplier delay or logistics issue can raise unit costs and slow deliveries, which matters more for specialized hardware with limited production scale.
Selling, general and administrative
Selling, general and administrative expenses cover sales, marketing, finance, and corporate overhead, and for IceCure Medical Ltd they stay heavy because a global medtech company must fund commercial teams, regulatory support, and market-building. As IceCure expands abroad, SG&A rises fast and can absorb a large share of operating spend before scale kicks in.
- Sales and marketing build demand.
- Finance and admin keep operations running.
- International growth lifts overhead.
Regulatory and legal compliance
Regulatory and legal compliance is a recurring cost for IceCure Medical Ltd, with FDA 510(k) reviews often targeted at about 90 days and EU MDR certificates lasting 3–5 years, so filings, audits, and legal support stay in the budget through each product change. This spend helps keep market access open and cuts delay, recall, and enforcement risk.
- Ongoing filings and audits
- Legal support across product life cycle
- Protects approvals and market access
IceCure’s Regulatory Costs Keep Repeating with Every Product Update
IceCure Medical Ltd’s cost structure is dominated by R&D, clinical trials, manufacturing, SG&A, and compliance. FDA 510(k) reviews often target about 90 days, while EU MDR certificates can run 3–5 years, so regulatory spend stays recurring and tied to every product update.
| Cost item | Key driver | Number |
|---|---|---|
| Regulatory | Approvals and audits | 90 days; 3–5 years |
Revenue Streams
ProSense system sales
ProSense system sales are IceCure Medical Ltd’s core capital-equipment revenue: hospitals and clinics buy the platform first, then use it for cryoablation procedures. That installed base is the key commercial engine, because each placement can support later disposables and procedure growth, which is why equipment sales sit at the center of the model.
Cryoablation probe sales
IceCure Medical Ltd's single-use cryoablation probes create repeat revenue each time a procedure is performed, so sales aren’t limited to the initial system install. Consumables like these lift lifetime customer value because hospitals must keep buying new probes for ongoing use, not just capital equipment.
Accessories and service
Accessories, maintenance, and support can add recurring income for IceCure Medical Ltd, and that matters because medical equipment sales are often lumpy. Service revenue also helps steady cash flow after placements, since hospitals usually expect ongoing technical support for installed systems.
This stream is common across the medtech sector, and it can improve lifetime value per customer even when the core device sale is one-time.
Distributor-based sales
IceCure Medical Ltd uses international distributors to resell products, so the Company can grow across markets without building full local sales teams everywhere. This model supports geographic scale, and revenue can flow through distributor margins or transfer pricing, which helps keep market entry costs lower.
- Resale through overseas distributors
- Lower direct-market setup costs
- Revenue via margins or transfer pricing
- Best for fast geographic expansion
Replacement and expansion orders
Replacement and expansion orders can turn an installed IceCure Medical Ltd system into a recurring revenue stream, as existing customers add units, probes, and other consumables over time. After early clinical use proves value, new departments or sites may adopt the platform too, which makes repeat orders more predictable and is a key medtech growth driver.
- More units and supplies from existing customers
- New sites can expand after early success
- Repeat orders lift revenue visibility
IceCure’s Revenue Mix: Systems, Recurring Probes, and Distributor Support
IceCure Medical Ltd’s revenue is still led by ProSense system placements, then lifted by repeat probe sales, which are the main recurring line. Distributor-led sales also support expansion without a full local sales buildout, while service and replacement orders help smooth the lumpiness of capital equipment sales.
| Stream | FY2025 role | Type |
|---|---|---|
| ProSense systems | Core install revenue | One-time |
| Single-use probes | Repeat procedure sales | Recurring |
| Distributors and service | Geographic scale and support | Recurring |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.